BR112016016153A2 - composições de enolase 1 (eno1) e usos das mesmas - Google Patents
composições de enolase 1 (eno1) e usos das mesmasInfo
- Publication number
- BR112016016153A2 BR112016016153A2 BR112016016153A BR112016016153A BR112016016153A2 BR 112016016153 A2 BR112016016153 A2 BR 112016016153A2 BR 112016016153 A BR112016016153 A BR 112016016153A BR 112016016153 A BR112016016153 A BR 112016016153A BR 112016016153 A2 BR112016016153 A2 BR 112016016153A2
- Authority
- BR
- Brazil
- Prior art keywords
- eno1
- enolase
- individual
- subject
- blood glucose
- Prior art date
Links
- 101150015836 ENO1 gene Proteins 0.000 title abstract 4
- 101100172356 Schizosaccharomyces pombe (strain 972 / ATCC 24843) eno101 gene Proteins 0.000 title abstract 4
- 101100172357 Schizosaccharomyces pombe (strain 972 / ATCC 24843) eno102 gene Proteins 0.000 title abstract 4
- 101710165425 Alpha-enolase Proteins 0.000 title abstract 3
- 102100038910 Alpha-enolase Human genes 0.000 title abstract 3
- 101710184673 Enolase 1 Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000008103 glucose Substances 0.000 abstract 3
- 210000003205 muscle Anatomy 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926913P | 2014-01-13 | 2014-01-13 | |
| US201462009783P | 2014-06-09 | 2014-06-09 | |
| US201562100881P | 2015-01-07 | 2015-01-07 | |
| PCT/US2015/011275 WO2015106295A2 (en) | 2014-01-13 | 2015-01-13 | Enolase 1 (eno1) compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016016153A2 true BR112016016153A2 (pt) | 2017-12-12 |
Family
ID=53524434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016016153A BR112016016153A2 (pt) | 2014-01-13 | 2015-01-13 | composições de enolase 1 (eno1) e usos das mesmas |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10188708B2 (https=) |
| EP (2) | EP3094379A4 (https=) |
| JP (2) | JP6629234B2 (https=) |
| KR (1) | KR20160106175A (https=) |
| CN (3) | CN112336851A (https=) |
| AU (2) | AU2015204452A1 (https=) |
| BR (1) | BR112016016153A2 (https=) |
| CA (2) | CA2936691A1 (https=) |
| EA (1) | EA201691420A1 (https=) |
| HK (1) | HK1231425A1 (https=) |
| IL (1) | IL246720A0 (https=) |
| MX (1) | MX2016009102A (https=) |
| SG (1) | SG11201605698XA (https=) |
| WO (2) | WO2015106295A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015204452A1 (en) * | 2014-01-13 | 2016-08-11 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| WO2016210008A1 (en) * | 2015-06-22 | 2016-12-29 | Berg Llc | Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain |
| WO2017062363A1 (en) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| US20200185063A1 (en) | 2016-06-05 | 2020-06-11 | Berg Llc | Systems and methods for patient stratification and identification of potential biomarkers |
| CN107991493B (zh) * | 2017-11-22 | 2020-03-31 | 中国医科大学附属第一医院 | 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用 |
| CN112111462B (zh) * | 2020-09-14 | 2022-08-23 | 兰州大学 | 烯醇化酶eno1单克隆抗体及其应用 |
| EP4436613A4 (en) * | 2021-11-26 | 2025-11-12 | Hunilife Biotechnology Inc | METHODS OF GLYCOLYSIS REGULATION BY TARGETING EXTRACELLULAR ALPHA-ENOLASE FOR THE TREATMENT OF HUMAN DISEASES |
| CN114533902A (zh) * | 2022-02-28 | 2022-05-27 | 河南师范大学 | 一种过表达lrrc15基因的质粒载体及其制备方法和应用 |
| CN115786317B (zh) * | 2022-12-12 | 2026-03-20 | 江苏三联生物工程股份有限公司 | 重组神经元特异性烯醇化酶及其制备方法与应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1350523B1 (en) | 1992-09-25 | 2007-05-16 | Boston Scientific Limited | Therapeutic conjugates inhibiting vascular smooth muscle cells |
| IL115766A0 (en) | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US20030044795A1 (en) | 1996-09-06 | 2003-03-06 | Inger Byrajalsen | Biochemical markers of the human endometrium |
| US7078375B1 (en) * | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
| US6329501B1 (en) | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| IL148225A0 (en) | 1999-09-01 | 2002-09-12 | Subsidiary No 3 Inc | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2001030973A2 (en) | 1999-10-25 | 2001-05-03 | Princeton University | Genetic sequences associated with neural cell proliferation and disease |
| CA2399058A1 (en) * | 2000-02-02 | 2001-08-09 | Transgene S.A. | Targeting peptides |
| WO2004043361A2 (en) | 2002-11-08 | 2004-05-27 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
| US20030203372A1 (en) | 2000-12-08 | 2003-10-30 | Ward Neil Raymond | Analysis method |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| US20040058326A1 (en) | 2001-07-27 | 2004-03-25 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
| US20050191627A1 (en) | 2001-09-28 | 2005-09-01 | Incyte Corporation | Enzymes |
| WO2003064501A1 (en) * | 2002-01-31 | 2003-08-07 | Clarke Slemon | Conformationally restricted compounds as dendrimer cores |
| US20050222023A1 (en) | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
| JP2004081111A (ja) | 2002-08-27 | 2004-03-18 | Yamaguchi Technology Licensing Organization Ltd | 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法 |
| CN101518533A (zh) * | 2002-12-06 | 2009-09-02 | 法布罗根股份有限公司 | 脂肪调节 |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| WO2004055519A2 (en) | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| AU2003300178A1 (en) | 2002-12-30 | 2004-07-29 | Ppd Development, Lp | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2004084950A2 (en) | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Cell targeting methods and compositions |
| US7473531B1 (en) | 2003-08-08 | 2009-01-06 | Colora Corporation | Pancreatic cancer targets and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005073621A (ja) | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | 脳腫瘍マーカーと脳腫瘍の診断方法 |
| WO2005032572A2 (en) | 2003-10-03 | 2005-04-14 | Vib Vzw | Means and methods for the recruitment and identification of stem cells |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| CA2513317A1 (en) | 2004-07-06 | 2006-01-06 | Kuhnil Pharmaceutical Co., Ltd. | Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it |
| WO2007046818A2 (en) | 2004-11-16 | 2007-04-26 | Board Of Regents, The University Of Texas System | Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display |
| WO2006073254A1 (en) | 2005-01-03 | 2006-07-13 | Sook-Yeong Jeon | Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US20070248628A1 (en) | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| TWI304443B (en) | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| WO2008012362A2 (en) | 2006-07-27 | 2008-01-31 | Oxford Genome Sciences (Uk) Ltd | New protein isoforms and uses thereof |
| ATE542831T1 (de) | 2006-09-29 | 2012-02-15 | Ribovax Biotechnologies Sa | Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind |
| US20100047256A1 (en) | 2007-01-25 | 2010-02-25 | Imperial Innovations Limited | Methods |
| JP2010526091A (ja) | 2007-04-30 | 2010-07-29 | インテザイン テクノロジーズ， インコーポレイテッド | 癌の処置のための生物学的な標的基の改変 |
| WO2009008727A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| JP5429707B2 (ja) | 2008-03-27 | 2014-02-26 | 国立大学法人群馬大学 | 微粒子およびその製造方法 |
| WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| JP2011528557A (ja) | 2008-07-18 | 2011-11-24 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 過体重動物と関連する障害を治療するための組成物および方法 |
| EP2194382A1 (en) | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| IT1398782B1 (it) | 2009-09-11 | 2013-03-18 | Novelli | Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi. |
| WO2011064552A1 (en) | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011072290A2 (en) | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| US20130072437A1 (en) | 2010-05-28 | 2013-03-21 | Mind-Nrg Sa | Neuregulin isoforms,neuregulin polypeptides and uses thereof |
| EP2638058B1 (en) | 2010-11-12 | 2017-01-11 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| JP2014517832A (ja) * | 2011-05-10 | 2014-07-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 自己免疫疾患を治療するための方法及び医薬組成物 |
| GB201113814D0 (en) | 2011-08-10 | 2011-09-28 | Proteome Sciences R & D Gmbh & Co Kg | Materials and methods for determining sensitivity potential of compounds |
| CN103998458B (zh) | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| IN2014DN05803A (https=) | 2011-12-14 | 2015-05-15 | Univ Texas | |
| US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| WO2014070723A1 (en) | 2012-10-30 | 2014-05-08 | Particle Sciences, Inc. | Drug delivery particle formulations with targeting moieties |
| AU2015204452A1 (en) * | 2014-01-13 | 2016-08-11 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
| WO2016210008A1 (en) | 2015-06-22 | 2016-12-29 | Berg Llc | Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain |
| EP3322405A4 (en) | 2015-07-16 | 2019-01-23 | Berg LLC | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF |
-
2015
- 2015-01-13 AU AU2015204452A patent/AU2015204452A1/en not_active Abandoned
- 2015-01-13 CA CA2936691A patent/CA2936691A1/en not_active Abandoned
- 2015-01-13 JP JP2016563909A patent/JP6629234B2/ja not_active Expired - Fee Related
- 2015-01-13 CN CN202011098097.6A patent/CN112336851A/zh active Pending
- 2015-01-13 CN CN201580012892.XA patent/CN106659766B/zh active Active
- 2015-01-13 MX MX2016009102A patent/MX2016009102A/es unknown
- 2015-01-13 US US14/596,208 patent/US10188708B2/en active Active
- 2015-01-13 JP JP2016563908A patent/JP6644006B2/ja not_active Expired - Fee Related
- 2015-01-13 CA CA2936694A patent/CA2936694A1/en not_active Abandoned
- 2015-01-13 EP EP15735142.0A patent/EP3094379A4/en not_active Withdrawn
- 2015-01-13 EP EP15735001.8A patent/EP3094341B1/en active Active
- 2015-01-13 EA EA201691420A patent/EA201691420A1/ru unknown
- 2015-01-13 HK HK17105147.2A patent/HK1231425A1/zh unknown
- 2015-01-13 SG SG11201605698XA patent/SG11201605698XA/en unknown
- 2015-01-13 CN CN201580012874.1A patent/CN106102835B/zh not_active Expired - Fee Related
- 2015-01-13 WO PCT/US2015/011275 patent/WO2015106295A2/en not_active Ceased
- 2015-01-13 KR KR1020167022300A patent/KR20160106175A/ko not_active Withdrawn
- 2015-01-13 AU AU2015204451A patent/AU2015204451A1/en not_active Abandoned
- 2015-01-13 US US14/596,207 patent/US10188707B2/en active Active
- 2015-01-13 WO PCT/US2015/011276 patent/WO2015106296A1/en not_active Ceased
- 2015-01-13 BR BR112016016153A patent/BR112016016153A2/pt not_active Application Discontinuation
-
2016
- 2016-07-11 IL IL246720A patent/IL246720A0/en unknown
-
2018
- 2018-11-28 US US16/202,989 patent/US11224641B2/en active Active
- 2018-11-28 US US16/203,016 patent/US20190307864A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016016153A2 (pt) | composições de enolase 1 (eno1) e usos das mesmas | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| BR112017021311A2 (pt) | composições farmacêuticas para terapia de combinação | |
| BR112018003745A2 (pt) | composições que compreendem um composto de urolitina | |
| MX2021010329A (es) | Composicion farmaceutica que comprende empagliflozina y sus usos. | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| BR112013010021A2 (pt) | combinações farmacêuticas para o tratamento de distúrbios metabólicos. | |
| BR112018000639A2 (pt) | sistema de cateter funcionalmente integrável | |
| BR112016010422A8 (pt) | suplemento dietético, e uso de uma composição | |
| BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
| BR112016028672A2 (pt) | análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo | |
| BR112017025339A2 (pt) | composições nutricionais contendo um nível elevado de inositol e usos das mesmas | |
| BR112018000641A8 (pt) | Sistema de cateter funcionalmente integrável | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
| BR112017006416A2 (pt) | composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico | |
| BR112015003399A2 (pt) | métodos e composições úteis para melhorar a saúde óssea e articular | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| BR112017000978A2 (pt) | mioinositol e probióticos e usos | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
| BR112019001459A2 (pt) | combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio. | |
| BR112017025189A2 (pt) | composição e usos da mesma | |
| MX2018004489A (es) | Extracto de agavaceae que comprende saponinas esteroidales y su uso para tratar y/o prevenir patologías relacionadas con desórdenes metabólicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |